Test ID: JAK2B
JAK2 V617F Mutation Detection, Blood
NY State Approved 
Indicates the status of NY State approval and if the test is orderable for NY State clients.
Yes
Useful For Suggests clinical disorders or settings where the test may be helpful
Aiding in the distinction between a reactive cytosis and a chronic myeloproliferative disorder
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
The following algorithms are available in Special Instructions:
-Erythrocytosis Evaluation Testing Algorithm
-Myeloproliferative Neoplasm: A Diagnostic Approach to Peripheral Blood Evaluation
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Method Name A short description of the method used to perform the test
Point Mutation Detection in DNA Using Quantitative Polymerase Chain Reaction (PCR)
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
JAK2 V617F Mutation Detection, B
Aliases Lists additional common names for a test, as an aid in searching
Janus kinase 2 gene
83872-JAK2B
Tyrosine Kinase Mutation
83872-JAK2B
Tyrosine Kinase Mutation
External
link
PDF
document
Excel
document
Word
document